Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.
Journal of psychoactive drugs January 1, 2024 Kelan L Thomas, Robert Jesse, Nicky J Mehtani et al. 4 citations
Policymakers are increasingly using clinical trial data to justify deprioritizing, decriminalizing, or legalizing psychedelic substances, but personal possession limits written into law often lack scientific grounding. This commentary argues that allowable amounts should be based on moderate-high doses shown safe and effective in clinical trials, common naturalistic use, and dose-equivalence studies. The authors provide a table of evidence-informed moderate-high doses for seven psychedelics to guide consistent and equitable policy limits, aiming to replace arbitrary thresholds with scientifically justified ones.